Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 46

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 46
---
 has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of warrants or stock options or the vesting of restricted stock units, within 60 days of July 3, 2025. Shares subject to warrants or options that are currently exercisable or exercisable within 60 days of July 3, 2025 or subject to restricted stock units that vest within 60 days of July 3, 2025 are considered outstanding and beneficially owned by the person holding such warrants, options, or restricted stock units for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

Except as noted by footnote, and subject to community property laws where applicable, based on the information provided to the Company, the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise indicated, the business address of each beneficial owner listed in the table below is c/o Conduit Pharmaceuticals Inc., 4851 Tamiami Trail North, Suite 200, Naples, FL 34103.

The beneficial ownership of our Common Stock is based on 2,405,140 shares of Common Stock issued and outstanding as of July 3, 2025, which number excludes the shares of Common Stock issuable upon exercise of the warrants. Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all of the shares shown to be beneficially owned by them.

| Name and Address of Beneficial Owner(1)                         |     | Number of shares of Common Stock |         |    |     | % of Common Stock* |      |   |
| Directors and executive officers                                |     |                                  |         |    |     |                    |      |   |
| James Bligh                                                     |     |                                  |     692 | -2 |     |                    |    * |   |
| Chele Chiavacci Farley                                          |     |                                  |   2,529 | -3 |     |                    |    * |   |
| Freda Lewis-Hall                                                |     |                                  |   5,516 | -4 |     |                    |    * |   |
| Andrew Regan                                                    |     |                                  | 174